| Name | Title | Contact Details |
|---|
Johnson and Johnson Vision Care is a company committed to transforming the world's vision. Since our inception, we have strived to increase awareness of the importance of vision and vision care and to provide the world's most exceptional vision correction
MemoryWell is a digital platform that uses life storytelling to improve the care of elders. Using our network of more than 700 professional writers, we work with families, senior living communities and home- and community-based providers to replace burdensome intake questionnaires with brief, intimate stories designed to build empathy and be poignant keepsakes for families. Families can add to them their loved one`s favorite photos, music and movies so whomever is sitting with them—whether it`s a paid caregiver, or a grandchild—they have a whole toolbox of things with which to engage that senior.
Access Case Management Services of Georg is a Savannah, GA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Ridgway Community Nurse Service Inc is a Washington, DC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Neuralstem is a dual platform regenerative medicine company. The company`s technology enables the production of regionally specific, physiologically relevant neural stem cells for therapeutic use for the treatment of central nervous system (CNS) diseases and has enabled the discovery of a library of patented small molecule neurogenic compounds to treat psychological and cognitive disorders. Neuralstem`s small molecule drug discovery program screens human neural stem cell lines for compounds that may stimulate neurogenesis in the brain, possibly reversing pathologies associated with certain CNS conditions. The company`s lead compound, NSI-189, has completed FDA Phase Ia and Ib safety trials for the treatment of major depressive disorder (MDD). Neuralstem is expecting to launch a Phase II study for MDD in 2015. Neuralstem`s first stem cell therapy product, NSI-566, a spinal cord-derived neural stem cell line, is in ongoing clinical trials to treat amyotrophic lateral sclerosis (ALS, or Lou Gehrig`s disease), for which it has received orphan status designation by the FDA. Dosing in a phase IIa trial was completed in July, 2014. The next trial is anticipated to commence in 2015. In addition to ALS, the company is conducting an NSI-566 Phase I trial in chronic spinal cord injury, with NSI-566 clinical development also underway to treat ischemic